

VRL/SEC/EXCHANGE

19.08.2022

BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers Dalal Street
Mumbai
Script Code: 526953


Sub.: Compliance pursuant to Regulation 46 of SEBI (LODR) Regulations, 2015.

Dear Sir/ Madam,

Please find enclosed herewith website Compliance pursuant to Regulation 46 of SEBI (LODR) Regulations, 2015.

Kindly take it on your record.

Yours faithfully,
for VENUS REMEDIES LIMITED


Neha
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :

51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :

SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.vmrindia.com
email : info@venusremedies.com
CIN No. : L24232CH1989PLC009705

Unit-I :

51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :

Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :

VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany



Sl. No.	Particulars as per LODR	Y/N/NA	URI	Remarks
1	(a) Details of business	Y	https://venusremedies.com/about	
2	(b) Terms and conditions of appointment of independent directors	Y	https://resources/pdf/terms conditions of ind directors.pdf	
3	(c) Composition of various committees of board of directors	Y	sources/pdf/investorpdf/Composition%20of%20Committees%202022_0.pdf	
4	(d) Code of conduct of board of directors and senior management personnel	Y	https://venusremedies.com/ethiccompliance	
5	(e) Details of establishment of vigil mechanism/ Whistle Blower policy	Y	https://venusremedies.com/ethiccompliance	
6	(f) Criteria of making payments to non-executive directors, if the same has not been disclosed in annual report	Y	https://venusremedies.com/ethiccompliance	
7	(g) Policy on dealing with related party transactions	Y	https://venusremedies.com/ethiccompliance	
8	(h) Policy for determining 'material' subsidiaries	Y	https://venusremedies.com/ethiccompliance	
9	(i) Details of familiarization programmes imparted to independent directors including the following details:- (i) Number of programmes attended by independent directors (during the year and on a cumulative basis till date) (ii) Number of hours spent by independent directors in such programmes (during the year and on cumulative basis till date), and (iii) Other relevant details	Y	https://resources/pdf/familiarization-programme-directors-cumulative-22.pdf	
10	(j) The email address for grievance redressal and other relevant details	Y	https://venusremedies.com/financialview	
11	(k) Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances (l) Financial information including: (i) Notice of meeting of the board of directors where financial results shall be discussed (ii) Financial results, on conclusion of the meeting of the board of directors where the financial results were approved (iii) Complete copy of the annual report including balance sheet, profit and loss account, directors report, corporate governance report etc.	Y	https://venusremedies.com/financialview	
12	(m) Shareholding pattern	Y	https://venusremedies.com/investorinformation , https://venusremedies.com/financialview	
13	(n) Details of agreements entered into with the media companies and/or their associates, etc.	NA	https://venusremedies.com/investorinformation	No agreement entered with Media Companies

15	(o) Schedule of analysts or institutional investors meet and presentations made by the listed entity to analysts or institutional investors. Explanation: For the purpose of this clause 'meet' shall mean group meetings or group conference calls conducted physically or through digital means (oa) Audio or video recordings and transcripts of post earnings/quarterly calls, by whatever name called, conducted physically or through digital means, simultaneously with submission to the recognized stock exchange(s), in the following manner: (i) The presentation and the audio/video recordings shall be promptly made available on the website and in any case, before the next trading day or within twenty-four hours from the conclusion of such calls, whichever is earlier (ii) The transcripts of such calls shall be made available on the website within five working days of the conclusion of such calls	NA		No Investor meet or presentation prepared
16	(p) New name and the old name of the listed entity for a continuous period of one year, from the date of the last name change	NA		Name not Changed
17	(q) Items published in the newspaper: (a) Financial results, as specified in regulation 33, along with the modified opinion(s) or reservation(s), if any, expressed by the auditor: (b) notices given to shareholders by advertisement.	Y	https://venusremedies.com/investorinformation	
18	(r) All credit ratings obtained by the entity for all its outstanding instruments, updated immediately as and when there is any revision in any of the ratings	NA		No Outstanding Instrument
19	(s) Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year, uploaded at least 21 days prior to the date of the annual general meeting which has been called to Inter alia consider accounts of that financial year	Y	https://venusremedies.com/financialview	
20	(t) Secretarial compliance report	Y	https://venusremedies.com/investorinformation	
21	(u) Disclosure of the policy for determination of materiality of events or information	Y	https://venusremedies.com/investorinformation	
22	(v) Disclosure of contact details of key managerial personnel who are authorized for the purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange(s)	Y	https://venusremedies.com/investorinformation	
23	(w) All such events or information which has been disclosed to stock exchange(s) under regulation 30 of LODR	Y	https://venusremedies.com/investorinformation	
24	(x) Statements of deviation(s) or variation(s)	NA		Not Applicable
25	(y) Dividend distribution policy by listed entities based on market capitalization	NA		Not applicable
26	(z) Annual return as provided under section 92 of the Companies Act, 2013 and the rules made thereunder.	Y	https://venusremedies.com/investorinformation	